Daily FNArena News - Australia

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure Chest

Previous Stories

The Implications Of A Runaway Aussie Dollar

Sep 22 2010

With the RBA in a hawkish mood, the Aussie seems destined to hit parity. But this has varying implications for stocks, inflation, the trade balance and monetary policy itself.


RBA Rate Rise Coming

Sep 21 2010

The minutes of the September RBA board meeting do little to dispel the belief interest rates will be on the move again soon.


Analysts Begin To Assume No BHP-Rio JV

Sep 21 2010

BHP’s bid for Potash was a clue, as was BHP and Rio’s request for an extension from the ACCC, but at least one broker has now removed the Pilbara JV from its valuation model.


The Economic Implications Of SYD-MEL

Sep 20 2010

If the Sydney-Melbourne air route is the third busiest in the world as of July, then Australia’s ex-mining economy can’t be all that bad, suggests CommSec.


Santos Takes Another Step Forward

Sep 20 2010

An impressive European hybrid issue is another incremental positive along the road to GLNG’s second train and a share price re-rating for Santos.


Myer Keeps Market Views Divided

Sep 17 2010

Myer met expectations with its full year profit result but stockbroker opinions on the stock remain mixed.


Unconventional Molopo Offers Value

Sep 16 2010

Molopo is developing unconventional oil deposits in Canada and while these imply additional risks there is significant upside on offer in the view of Macquarie.


Citi Not Sold On Beach Shale

Sep 16 2010

Citi sees some question markets for Beach Petroleum, as spending for growth has not been successful and there may be little value in the company’s shale assets.


Positive Momentum Continues For Graincorp

Sep 15 2010

On the back of increased expectations for Australia’s winter crop production, stockbrokers have lifted forecasts and price targets for major beneficiary Graincorp.


QRxPharma: The Next Australian Growth Stock?

Sep 15 2010

Southern Cross Equities has initiated coverage on QRxPharma with a Speculative Buy rating, seeing the group’s MoxDuo drug as a potential company maker.



Analyse The Market From A Different Angle